Related Experiment Video

Updated: Mar 13, 2026

Author Spotlight: Advancements and Challenges in Hepatitis B Virus Detection
04:11

Author Spotlight: Advancements and Challenges in Hepatitis B Virus Detection

Published on: December 15, 2023

5.0K

Prevalence and clinical implications of IL28B genotypes in Taiwanese patients with chronic hepatitis C

Yone-Han Mah1, Chen-Hua Liu2, Chi-Ling Chen3

  • 1Division of Gastroenterology, Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan; Department of Internal Medicine, Lotung St Mary's Hospital, I-Lan, Taiwan.

Journal of the Formosan Medical Association = Taiwan Yi Zhi
|October 19, 2016
PubMed

Insights

Chronic hepatitis C patients in Taiwan show lower frequencies of the favorable IL28B TT genotype. This genotype is linked to reduced advanced fibrosis, especially in females with hepatitis C virus genotype 2.

Area of Science:

  • Genetics
  • Hepatology
  • Virology

Background:

  • The IL28B gene's role in Taiwanese chronic hepatitis C (CHC) patients is not well understood.
  • Investigating IL28B rs8099917 genotypes in CHC patients and healthy controls is crucial.

Purpose of the Study:

  • To determine the prevalence of IL28B rs8099917 genotypes in Taiwanese CHC patients and healthy controls.
  • To explore the clinical implications of IL28B rs8099917 genotypes concerning hepatitis C virus (HCV) genotypes, liver disease severity, and patient demographics.

Main Methods:

  • Genotyping of IL28B rs8099917 was performed on 200 CHC patients with HCV genotype 1, 200 CHC patients with HCV genotype 2, and 197 healthy controls.
  • Associations between IL28B rs8099917 genotype and baseline characteristics (HCV RNA level, HCV genotype, histology, fibrosis stage, BMI) were analyzed using logistic regression, stratified by covariates.

Main Results:

  • CHC patients exhibited a lower prevalence of the favorable IL28B rs8099917 TT genotype compared to healthy controls (81.0% vs. 89.3%, p=0.025).
  • The TT genotype was less frequent in CHC patients with HCV genotype 1 (76.0%) than with HCV genotype 2 (86.0%, p=0.007).
  • Higher fibrosis stages were associated with a lower prevalence of the TT genotype (p=0.033), particularly in female patients (p=0.024).

Conclusions:

  • Taiwanese CHC patients demonstrate a reduced frequency of the favorable IL28B TT genotype compared to healthy individuals.
  • The TT genotype is more prevalent in CHC patients with HCV genotype 2 than genotype 1.
  • The IL28B TT genotype is associated with a lower likelihood of advanced fibrosis in CHC patients, with a more pronounced effect observed in females.
Abstract

Keywords:
IL28B polymorphismgenderhepatic fibrosishepatitis C virus genotypehistologyliver biopsyprevalence

More Related Videos

Detection of Low Copy Number Integrated Viral DNA Formed by In Vitro Hepatitis B Infection11:14

Detection of Low Copy Number Integrated Viral DNA Formed by In Vitro Hepatitis B Infection

Published on: November 7, 2018

18.9K
A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

2.7K

Related Concept Videos

Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
19.4K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
61